An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. (2015)
Attributed to:
Targeting the innate immune system in Huntington's disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bcp.12512
PubMed Identifier: 25223731
Publication URI: http://europepmc.org/abstract/MED/25223731
Type: Journal Article/Review
Volume: 79
Parent Publication: British journal of clinical pharmacology
Issue: 3
ISSN: 0306-5251